Malignant pleural effusion survival prognostication in an Asian population
- PMID: 32390227
- DOI: 10.1111/resp.13837
Malignant pleural effusion survival prognostication in an Asian population
Abstract
Background and objective: LENT and PROMISE scores prognosticate survival in patients with MPE. Prognostication guides the selection of interventions and management. However, the predictive value of these scores and their refinements (modified-LENT) in Asians remain unclear. We aim to evaluate the performance of LENT, modified-LENT and clinical PROMISE scores; identify predictors of survival; and develop an alternative prognostication tool should current scores lack accuracy.
Methods: Retrospective medical record review of an Asian pleuroscopy database from 2011 to 2018 of patients with MPE was conducted. The prognostic capability of current available scores were evaluated using C-statistics. Demographic and clinical variables as predictors of survival were assessed, and an alternative model was developed using logistic regression.
Results: In 130 patients, the C-statistics for modified-LENT was not significantly different from LENT (0.59 (95% CI: 0.52-0.67) vs 0.56 (95% CI: 0.49-0.63); P = 0.403). In 57 patients, the PROMISE C-statistics was 0.72 (95% CI: 0.53-0.91). In our alternative prognostication model (n = 147), Sex, Eastern Cooperative Oncology Group status, Leukocyte count, EGFR mutation, Chemotherapy and primary Tumour type (SELECT) were predictors of 90-day mortality (C-statistic = 0.87 (95% CI: 0.79-0.95)). SELECT sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios using a predicted probability of 90-day mortality cut-off point of 10% were 0.91, 0.68, 0.34, 0.98, 2.83 and 0.13, respectively.
Conclusion: The LENT, modified-LENT and PROMISE scores have poor accuracy of survival prognostication in Asian patients with MPE undergoing pleuroscopy. The proposed SELECT prognostication model is accurate at identifying patients with high probability of survival at 90 days.
Trial registration: ClinicalTrials.gov NCT01374542.
Keywords: cancer; malignant pleural effusion; mortality; prognosis; therapy.
© 2020 Asian Pacific Society of Respirology.
Comment in
-
Prognostication in malignant pleural effusion: One size does not fit all.Respirology. 2020 Dec;25(12):1229-1230. doi: 10.1111/resp.13916. Epub 2020 Jul 30. Respirology. 2020. PMID: 32734601 No abstract available.
References
REFERENCES
-
- Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am. J. Med. 1977; 63: 695-702.
-
- Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65(Suppl. 2): ii32-40.
-
- Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, YCG L, Lewis SZ, Maskell NA et al. Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. Am. J. Respir. Crit. Care Med. 2018; 198: 839-49.
-
- Bhatnagar R, Keenan EK, Morley AJ, Kahan BC, Stanton AE, Haris M, Haris M, Harrison RN, Mustafa RA, Bishop LJ et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N. Engl. J. Med. 2018; 378: 1313-22.
-
- Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, Davies CWH, Grayez J, Harrison R, Prasad A et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307: 2383-9.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
